How Much Upside is Left in Akero Therapeutics, Inc. (AKRO)? Wall Street Analysts Think 29.22%Zacks Investment Research • 05/23/23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common StockGlobeNewsWire • 05/16/23
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/15/23
Here's Why Momentum in Akero Therapeutics, Inc. (AKRO) Should Keep goingZacks Investment Research • 05/10/23
Akero Therapeutics: Proof Of Concept With EFX, Sets Up Catalyst Opportunities In 2023Seeking Alpha • 05/09/23
Akero Therapeutics: Excellent Data, Solid Clinical Potential, No Major Near Term CatalystsSeeking Alpha • 05/07/23
Can Akero Therapeutics, Inc. (AKRO) Climb 42.57% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 04/18/23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASHGlobeNewsWire • 03/29/23
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/17/23
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial StrategyGlobeNewsWire • 01/10/23
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/23
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 MilestonesGlobeNewsWire • 12/21/22
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD's The Liver Meeting® 2022GlobeNewsWire • 11/07/22
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/04/22
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 202224/7 Wall Street • 10/25/22
These Are the Five Best and Worst Performing Small-cap Stocks in September 202224/7 Wall Street • 10/22/22
These Were The Five Best And Worst Performing Healthcare Stocks In September 202224/7 Wall Street • 10/17/22